Hangzhou Tigermed Consulting , Ltd EBIT

The latest EBIT for HNGZY is $1.7B as of June 2026. That compares with $510M in the prior-year period — up 237.4% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Hangzhou Tigermed Consulting , Ltd's historical trend and sector peers before judging valuation or financial health.

Over the past year, HNGZY's EBIT moved from $510M to $1.7B — a 237.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Hangzhou Tigermed Consulting , Ltd's operating scale or balance-sheet position.

Against Healthcare companies, HNGZY currently prints $1.7B for EBIT, while the sector average sits near $1.9T. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Hangzhou Tigermed Consulting , Ltd's growth, margins, and balance sheet.

A EBIT figure of $1.7B for HNGZY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting HNGZY's EBIT ($1.7B), review year-over-year change from $510M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.